1. Home
  2. NTRS vs ILMN Comparison

NTRS vs ILMN Comparison

Compare NTRS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Trust Corporation

NTRS

Northern Trust Corporation

HOLD

Current Price

$176.11

Market Cap

32.6B

Sector

Finance

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$241.89

Market Cap

32.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRS
ILMN
Founded
1889
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6B
32.3B
IPO Year
2007
2000

Fundamental Metrics

Financial Performance
Metric
NTRS
ILMN
Price
$176.11
$241.89
Analyst Decision
Hold
Hold
Analyst Count
12
17
Target Price
$163.55
$124.24
AVG Volume (30 Days)
848.5K
2.0M
Earning Date
04-21-2026
04-30-2026
Dividend Yield
1.94%
N/A
EPS Growth
N/A
170.87
EPS
2.71
2.22
Revenue
$8,086,400,000.00
$4,343,000,000.00
Revenue This Year
$8.40
$6.47
Revenue Next Year
$4.13
$5.58
P/E Ratio
$65.35
$110.44
Revenue Growth
N/A
N/A
52 Week Low
$121.12
$88.00
52 Week High
$195.78
$246.76

Technical Indicators

Market Signals
Indicator
NTRS
ILMN
Relative Strength Index (RSI) 35.76 68.23
Support Level $174.81 $116.43
Resistance Level $178.70 N/A
Average True Range (ATR) 3.84 9.00
MACD -1.28 2.48
Stochastic Oscillator 8.67 83.58

Price Performance

Historical Comparison
NTRS
ILMN

About NTRS Northern Trust Corporation

Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2025, Northern Trust had assets under custody or administration of $18.7 trillion and assets under management of $1.8 trillion.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: